Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alteogen, 3SBio Agree Pact For ‘Biobetter’ Trastuzumab ADC

This article was originally published in PharmAsia News

Executive Summary

Chinese biotech 3SBio has licensed greater China rights to Alteogen’s novel trastuzumab-containing antibody-drug conjugate for breast cancer, in a deal that will expand 3SBio’s biologics pipeline and eventually provide competition in the indication to major firms including Roche.

You may also be interested in...



Alteogen Eyes ASEAN, OIC Biosimilar Markets Via Malaysian JV

Alteogen is taking a different strategy versus its bigger South Korean biosimilar rivals as it is aiming to enter the ASEAN and OIC biosimilar markets by establishing a joint venture with a state-owned Malaysian firm.

Alteogen Eyes ASEAN, OIC Biosimilar Markets Via Malaysian JV

Alteogen is taking a different strategy versus its bigger South Korean biosimilar rivals as it is aiming to enter the ASEAN and OIC biosimilar markets by establishing a joint venture with a state-owned Malaysian firm.

Should Pharma Be Concerned About Cooling China-Korea Ties?

Despite regional defense policy concerns that have prompted broad moves to limit economic exchanges between China and South Korea, which could also potentially affect ever expanding healthcare collaborations between the two countries, the pharma sector impact so far appears to be limited.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC088432

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel